UBS O'Connor’s Amylyx Pharmaceuticals AMLX Stock Holding History

UBS O'Connor’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,000	Closed	-$641K	–	514
2023 Q3	$641K	Sell	35,000 -4,000	-10%	-$84.6K	0.01%	373
2023 Q2	$841K	Buy	+39,000	New	+$1.05M	0.02%	399

Other funds holding AMLX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's AMLX Position: Q4 2023 in Review

UBS O'Connor sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 35,000 shares — an estimated $641K sold.

UBS O'Connor first reported a position in AMLX in Q2 2023 and held it in 2 quarters. The position peaked at $841K in Q2 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

UBS O'Connor reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 35,000 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $641K.
UBS O'Connor first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 2 quarters.
UBS O'Connor's Amylyx Pharmaceuticals position peaked at $841K in Q2 2023.
178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.